| Name | Title | Contact Details |
|---|
Minimax is a West Hempstead, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gnathos Dental Products is a Union, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NuVasive® is an innovative medical device company focused on developing minimally disruptive surgical products and procedures for the spine. Our mission is to improve the lives of patients who suffer from debilitating back, neck, or leg pain by creating cutting-edge products and procedures that revolutionize spine surgery through focusing on Speed of Innovation®, Absolute Responsiveness®, and Superior Clinical Results. Through innovative technological advancements, NuVasive has successfully progressed major spine surgery to where many patients have experienced extraordinary results—they are often walking the same day of surgery, experiencing less blood loss, spending less time in the hospital, and going back to work within four to six weeks (versus six months). NuVasive is the third largest medical device company in the global spine industry. We feature more than 90 products spanning lumbar, thoracic, and cervical applications, neuromonitoring services, and a biologics portfolio. Our products have been used in hundreds of thousands of spine surgeries. NuVasive had revenues of $811 million in 2015, including sales in over 30 countries, and employs more than 1,600 people globally. Corporate headquarters are in San Diego, California and Amsterdam, the Netherlands serves as international headquarters. The company has additional offices in the U.S. located in the states of Tennessee, Ohio, Maryland, and California. Internationally, NuVasive has additional offices located Puerto Rico, the United Kingdom, Germany, Italy, Australia, Spain, Singapore, and Japan.
SmarTest Corp. is a Independence, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date.